ALRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aileron Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6.89 Mil. Aileron Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $106.01 Mil.
The historical rank and industry rank for Aileron Therapeutics's Equity-to-Asset or its related term are showing as below:
During the past 9 years, the highest Equity to Asset Ratio of Aileron Therapeutics was 0.91. The lowest was -15.88. And the median was 0.65.
The historical data trend for Aileron Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aileron Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.61 | 0.74 | 0.91 | 0.85 | 0.07 |
Aileron Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.85 | 0.83 | 0.91 | 0.87 | 0.07 |
For the Biotechnology subindustry, Aileron Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aileron Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aileron Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aileron Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 6.887 | / | 106.008 | |
= |
Aileron Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Equity to Asset (Q: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 6.887 | / | 106.008 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aileron Therapeutics (NAS:ALRN) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Aileron Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
James Brian Windsor | officer: See Remarks | 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746 |
William Fairey | director | C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043 |
Alan A Musso | director | FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Susan L. Drexler | officer: See Remarks | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Muneer A Satter | 10 percent owner | C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611 |
Reinhard J. Ambros | director | C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139 |
Von Rickenbach Josef H | director | C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163 |
Jeffrey Allen Bailey | director | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612 |
Vojo Vukovic | officer: SVP, Chief Medical Officer | C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421 |
Kathryn Gregory | officer: SVP, Chief Business Officer | 305 THAYER POND ROAD, WILTON CT 06897 |
William Mckee | director | |
Nolan Howard Sigal | director | 941 BERRY AVENUE, LOS ALTOS CA 94024 |
Novartis Bioventures Ltd | 10 percent owner | C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000 |
Rick Wanstall | officer: VP, Finance and Operations | C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472 |
Longenecker John P Phd | officer: President and CEO | 10445 PACIFIC CENTER CT, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-09-2022
By GuruFocusNews GuruFocusNews • 06-16-2022
By PurpleRose PurpleRose • 07-15-2022
By Value_Insider Value_Insider • 11-30-2022
By PurpleRose PurpleRose • 07-12-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By Value_Insider Value_Insider • 10-26-2022
By PurpleRose PurpleRose • 08-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.